Stem Cells & Cell Differentiation: Potency, iPSCs & Medical Applications | Cambridge AS-Level Biology (9700)
Table of Content
- Introduction: What is a stem cell?
- Potency Hierarchy
- Totipotent vs Pluripotent vs Multipotent vs Unipotent
- Embryonic Stem Cells Vs adult Stem Cells.
- Medical Applications:
- Bone marrow transplant for Leukemia.
- Tissue repair & regenerative medicine.
- Advanced Concept (A2 / Section 19 Focus):
- iPSCs (Induced Pluripotent Stem Cells): Reprogramming somatic cells using transcription factors.
- Ethical Debate & Social Considerations:
- Embryonic Stem Cells (ESC) vs iPSCs (Destruction of blastocysts vs non-destructive alternative).
- AO1 Knowledge with Understanding (Direct & Recall Questions)
- AO2 Application of Knowledge (Diagram & Labeling Questions)
- AO3 Experimental Skills & Data Interpretation (Graph & Table Questions)
- Stem cells are undifferentiated biological cells that have the unique ability to continuously divide through mitosis and differentiate into specialized cell types.
- Ernest McCulloch and James Till are widely credited with pioneering stem cell discovery in medical research.
- Broadly, stem cells are categorized into two main types: Embryonic Stem Cells (ESCs) and Adult Stem Cells.
- The differentiation capacity of a stem cell depends on its potency level. Stem cells are categorized into four distinct potency levels:
- Totipotent Cells can differentiate into any cell type in the body, as well as extra-embryonic tissues (such as the placenta). Example: Early embryonic cells (Zygote up to early morula).
- Pluripotent Cells are capable of giving rise to almost all cell types derived from the three germ layers (ectoderm, mesoderm, and endoderm), but cannot form extra-embryonic tissues. Example: Inner cell mass of the blastocyst (Embryonic Stem Cells).
- Multipotent Cells are restricted to differentiating into a limited range of specialized cell types belonging to a specific lineage or tissue. Example: Hematopoietic stem cells in the bone marrow (which form red blood cells, white blood cells, and platelets).
- Unipotent Stem cells can divide to produce only one specific cell type, yet retain self-renewal properties. Example: Epidermal stem cells producing skin cells.
![]() |
| Figure: Hierarchy of Stem Cell Potency — From Totipotent (Zygote & Morula) to Pluripotent (Inner Cell Mass of Blastocyst) and Multipotent lineage differentiation. |
- Embryonic stem cells are isolated from the inner cell mass of the blastocyst during early embryonic development.
- ESCs are pluripotent. They have the capability to differentiate into almost any cell type derived from the three primary germ layers: ectoderm, mesoderm, and endoderm.
- ESC has great Differentiation Potential and can give rise to more than 200 distinct specialized cell types in the human body.
- Adult stem cells are undifferentiated cells found among specialized tissues in a fully developed organism, as well as in umbilical cord blood.
- Unlike embryonic stem cells, most naturally occurring adult stem cells are multipotent, meaning their differentiation is restricted to specific cell lineages related to their tissue of origin.
- Key Example include hematopoietic stem cells (forming blood cells), mesenchymal stem cells, and endothelial stem cells.
| Feature | Embryonic Stem Cells (ESCs) | Adult / Somatic Stem Cells |
|---|---|---|
| Source | Inner cell mass of the blastocyst (early stage embryo) | Specialized tissues in mature organisms & umbilical cord blood |
| Potency Level | Pluripotent (Can form all body cell types) | Multipotent (Restricted to specific cell lineages) |
| Differentiation Potential | Can differentiate into >200 distinct cell types (Ectoderm, Mesoderm, Endoderm) | Limited to specialized cells of their tissue of origin (e.g., blood, skin) |
| Lab Culturing & Growth | Easy to isolate and can divide indefinitely in lab cultures | Rare, difficult to isolate, and limited capacity for self-renewal |
| Immune Rejection Risk | Higher risk of immune rejection if genetically non-matching | Lower risk if autologous (harvested from the patient's own body) |
| Ethical Concerns | High (Requires destruction of human blastocysts) | Low (Non-destructive, harvested with consent) |
- Stem cell therapy (regenerative medicine) involves introducing healthy stem cells into damaged tissues to treat diseases, repair injuries, and restore biological function through controlled cell culture techniques.
- In Current Clinical Uses, Stem cells harvested from bone marrow and umbilical cord blood are routinely used to treat blood cancers, such as leukemia and lymphoma.
- In Autoimmune Conditions, They are also used in managing severe autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
- Advanced stem cell research promises revolutionary therapies for spinal cord injuries, neurodegenerative brain damage, myocardial infarction (heart damage), and type 1 diabetes.
- Stem cells also serve as essential tools in genetic research and targeted drug discovery.
- Induced Pluripotent Stem Cells (iPSCs) are fully differentiated adult somatic cells (such as skin fibroblasts) that have been genetically reprogrammed to re-enter a pluripotent state, behaving almost identically to embryonic stem cells (ESCs).
- The creation of iPSCs involves major four steps :
- Adult somatic cells (e.g., skin cells) are harvested from a patient.
- Specific genes encoding master transcription factors (commonly Oct4, Sox2, Klf4, and c-Myc—known as Yamanaka factors) are introduced into the somatic cells using viral vectors (such as retroviruses or lentiviruses).
- These transcription factors alter gene expression by switching off differentiation markers and reactivating genes responsible for pluripotency and self-renewal.
- The resulting iPSCs can then be stimulated with specific signaling molecules to differentiate into any required specialized cell type (e.g., cardiomyocytes, neurons).
![]() |
| Figure: Reprogramming adult somatic cells into iPSCs using Yamanaka transcription factors (Oct4, Sox2, Klf4, c-Myc). |
- In Overcoming Immune Rejection, Since iPSCs are derived directly from the patient’s own tissues (autologous cells), they do not trigger an immune response upon transplantation.
- In Disease Modeling & Drug Testing, Scientists can create patient-specific iPSCs to study complex genetic diseases in lab dishes (e.g., Parkinson's disease) and test drug toxicity safely.
- The use of stem cells in research and clinical therapies raises significant ethical, moral, and social questions.
- The primary debate centers on the source of the stem cells, specifically comparing Embryonic Stem Cells (ESCs) with Induced Pluripotent Stem Cells (iPSCs).
- Destruction of Human Blastocysts: ESCs are harvested from the inner cell mass of 4-to-5-day-old human blastocysts (often surplus embryos from IVF treatments).
- Extracting these cells destroys the embryo, raising moral concerns regarding the status of human life at the embryonic stage.
- Concerns exist regarding whether proper informed consent was obtained from donors, as well as the potential risk of commercializing human biological materials.
- ESCs divide rapidly and unpredictably; if not fully differentiated before transplantation, they pose a risk of forming benign tumors known as teratomas in patients.
- Induced Pluripotent Stem Cells (iPSCs) are created by reprogramming adult somatic cells (like skin or blood cells). No human embryos are destroyed in the process, resolving the core moral conflict associated with ESCs.
- Because iPSCs are derived from the patient's own tissue, they carry a significantly lower risk of immune rejection, reducing the need for immunosuppressive drugs.
- While iPSCs offer an ethical breakthrough, challenges remain regarding the safety of viral vectors used in genetic reprogramming and the potential reactivation of oncogenes (cancer-causing genes like c-Myc).
| Aspect | Embryonic Stem Cells (ESCs) | Induced Pluripotent Stem Cells (iPSCs) |
|---|---|---|
| Embryo Destruction | Yes (Blastocyst is destroyed) | No (Derived from adult skin/somatic cells) |
| Moral / Ethical Conflict | High (Embryonic life ethical debate) | Minimal / Very Low |
| Immune Rejection Risk | High (Requires immunosuppressive drugs) | Low (Patient-specific / Autologous match) |
| Primary Safety Concern | Teratoma (tumor) formation if undifferentiated | Viral vector safety & potential oncogene activation |
- Stem cell technology represents one of the most promising frontiers in modern biology and regenerative medicine.
- By bridging the gap between basic cell biology and therapeutic applications, stem cells offer unprecedented potential to treat previously incurable conditions—from neurodegenerative disorders to genetic diseases.
- While Embryonic Stem Cells (ESCs) provide vital insights into developmental biology, breakthroughs like Induced Pluripotent Stem Cells (iPSCs) have opened ethical and patient-specific avenues for medical treatment.
- As genetic engineering and bioprinting technologies advance, stem cells will continue to play a pivotal role in personalizing healthcare and transforming the future of clinical medicine.
Question 2 : State the specific names of any TWO factors from X, Y, Z, or W used in this reprogramming process. [2 Marks]
Question 3 : Explain the role of retroviruses in this process and state ONE potential safety risk associated with using retroviral vectors. [2 Marks]
Answer 1 : Transcription factors (or Yamanaka factors / master gene regulatory proteins). [1 Mark]
Answer 2 : Any TWO of the following: Oct4, Sox2, Klf4, c-Myc. [2 Marks]
Answer 3 : Role: Retroviruses act as vectors to insert/integrate the genes encoding the transcription factors into the host cell genome. [1 Mark]
Safety Risk: Retroviruses can cause insertional mutagenesis (disrupting essential host genes or activating proto-oncogenes), which may lead to cancer/tumor formation. [1 Mark]
Context 2 : The diagram below illustrates a stem cell culture giving rise to various specialized cell types and tissues across different organ systems.
Question 1 : Based on the ability of these stem cells to differentiate into cells of the nervous system, digestive system, circulatory system, and skeletal system, state the potency level of the cultured stem cells shown. [1 Mark]
Question 2 : Identify the primary embryonic germ layers represented by the tissue labels P, Q, R, and S. [4 Marks] P (Brain / Neuron): ____ Q (Intestine / Enterocytes): ____ R (Bone / Osteocyte): ____ S (Heart / Cardiac cells): ____
Answer 3 : Differentiate between adult stem cells found in the brain (neural stem cells) and those found in the bone marrow (hematopoietic stem cells). [3 Marks]
Answer 1 : Pluripotent (or Pluripotency). [1 Mark]
Answer 2 : P (Brain / Neuron): Ectoderm [1 Mark] Q (Intestines / Enterocytes): Endoderm [1 Mark] R (Bone / Osteocyte): Mesoderm [1 Mark] S (Heart / Cardiac cells): Mesoderm [1 Mark]
Answer 3 : While both are multipotent adult stem cells, neural stem cells originate from the ectoderm and are localized within specific niches of the central nervous system (such as the hippocampus). They are developmentally committed to producing only neural cell lineages, including neurons, astrocytes, and oligodendrocytes, and exhibit a very low natural regenerative rate in adults.
In contrast, hematopoietic stem cells in the bone marrow originate from the mesoderm and are lineage-restricted to forming blood cells, including red blood cells, white blood cells, and platelets. Unlike neural stem cells, hematopoietic stem cells possess a significantly higher rate of active self-renewal and continuous cell division to constantly replenish blood cells in the body.
๐ Join the Community! Get access to FREE Worksheets, PDF Notes, and discuss Lessons with experts and fellow students
๐ Join the Community! Get access to FREE Worksheets, PDF Notes, and discuss Lessons with experts and fellow students
๐AO3 Experimental Skills & Data Interpretation (Graph & Table Questions)
| Treatment Group | Transcription Factors Introduced | Initial Cell Count | Number of iPSC Colonies Formed | Reprogramming Efficiency (%) |
|---|---|---|---|---|
| Control | None (Empty Retrovirus) | 100,000 | 0 | 0.00% |
| Group A | Oct4 + Sox2 | 100,000 | 12 | 0.012% |
| Group B | Oct4 + Sox2 + Klf4 | 100,000 | 180 | 0.18% |
| Group C | Oct4 + Sox2 + Klf4 + c-Myc | 100,000 | 1,250 | [ Calculate in Q3(b) ] |
Question 1 : Identify the independent variable and dependent variable in this experiment.
Answer 1 : Independent Variable: The combination/number of transcription factors introduced (or type of gene treatment). Dependent Variable: Number of iPSC colonies formed / Reprogramming efficiency (%).
Question 2 : Calculate the reprogramming efficiency (%) for Group C.
๐ Next Steps
More Biology Hub Pages !
❓ In case of any doubt, Chat Directly: ๐ฌ Ask Your Doubt on WhatsApp
Share with the Friends ๐




Comments
Post a Comment